Therefore, even though CBM activation by BCL10 mutants promotes BTKi resistance, the enzyme nonetheless maintains key roles protecting tumor cells from apoptosis, overcome by inhibition and informing a highly promising combination with venetoclax. This evidence concerns the gene BCL10 and neoplasm.